Self-Emulsifying Omega-3 Composition for Fasting Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ω3 polyunsaturated fatty acid (ω3PUFA) preparations face challenges such as poor absorption when taken before meals, high moisture content leading to handling issues, and ethanol content causing volatility and intolerance in some patients, particularly those who cannot consume meals regularly or have limited water intake.
Innovation Solution
A self-emulsifying composition containing 50-95% ω3PUFA and 5-50% emulsifier with a hydrophilic lipophilic balance (HLB) of at least 10, with low or no ethanol, using emulsifiers like polyoxyethylene hydrogenated castor oil and lecithin, which allows for rapid absorption under fasting conditions and stable storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ω3PUFA is administered orally under fasting, then absorption is poor and plasma EPA concentration increase is smaller, but administration timing flexibility is reduced
Solution Approach 1:
The patent changes the physical-chemical parameters of the ω3PUFA preparation by converting it into a self-emulsifying composition with specific HLB value emulsifiers (≥10), allowing the formulation to self-emulsify in the gastrointestinal tract without requiring food-induced bile secretion, thereby enabling reliable absorption under fasting conditions
Solution Approach 2:
The patent introduces an intermediary substance (self-emulsifying composition with emulsifiers having HLB ≥10) that mediates between the lipophilic ω3PUFA and the aqueous gastrointestinal environment, enabling absorption without requiring food-induced bile secretion
2Stability of the object's composition
If conventional emulsion composition is used, then processing and storage stability is improved, but absorption rate under fasting is slow
Solution Approach 1:
The patent changes the emulsifier selection criteria from conventional emulsifiers to those with HLB value ≥10, which provides both self-emulsifying capability for rapid absorption and adequate stability, resolving the contradiction between stability and absorption rate
3Reliability
If high moisture content preparation is used, then absorption property is improved, but handling and storage becomes difficult
Solution Approach 1:
The patent changes the formulation approach by using a self-emulsifying composition that requires minimal or no water for preparation, yet achieves rapid absorption through self-emulsification in the gastrointestinal tract, thereby improving both handling ease and maintaining absorption property
4Reliability
If ethanol is used as solvent, then dissolution and absorption are improved, but volatility and patient intolerance increase
Solution Approach 1:
The patent replaces ethanol as solvent with a self-emulsifying system using emulsifiers having HLB ≥10, which acts as an intermediary to solubilize ω3PUFA in the gastrointestinal tract without the harmful effects of ethanol, thereby maintaining absorption while eliminating volatility and intolerance issues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition enables rapid and effective absorption of ω3PUFA, reducing side effects and improving compliance, especially for patients with restricted meal schedules or water intake, while minimizing ethanol-related issues and storage challenges.
Implementation Method 1
a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ω3PUFA and pharmaceutically acceptable salts and esters thereof; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10
Data Source
AI summary
This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.